Journal Browser

Journal Browser

Silymarin and Derivatives: From Biosynthesis to Health Benefits 2.0

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Natural Products Chemistry".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 257

Special Issue Editor

E-Mail Website
Guest Editor
1. Inserm Research Center UMR1231 "Lipids, Nutrition, Cancer", Université de Bourgogne, 7 Blvd Jeanne d’Arc, 21000 Dijon, France
2. Centre de Lutte Contre le Cancer Georges-François Leclerc Center, 21000 Dijon, France
Interests: polyhenols; flavonoids; degenerative age-related diseases; inflammation; cancers; chemosensitization; lipid metabolism
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Interest in natural bioactive molecules has grown considerably over recent years due to the scientific work carried out by many researchers around the world and the growing interest of biotechnology companies and consumers in natural molecules with potential human health benefits. Among these compounds, flavonolignans are a family of natural products present in plants, composed of a flavonoid moiety and a phenylpropanoid or lignan part, that can contribute to new strategies to fight various modern pathologies (vascular diseases, cancers, degenerative diseases and associated inflammatory effects). In this context, one of the most important compounds of flavonolignans is represented by the SILYMARIN which is extracted from the milk thistle seeds, and that could act a chemopreventive compound or a therapeutic adjuvant.

This Special Issue follows the first edition of the same Issue (, published in Molecules, which was able to highlight the current knowledge of biosynthesis and health properties of silymarin and its derivatives, as well as the latest scientific advances in various domains, including bioavailability, cancer, inflammation and immunity, age-related degeneration and metabolism-related pathologies.

I invite authors to contribute original articles and review articles that provide the readers of Molecules with new and updated perspectives of Silymarin and its derivatives. It is our aim that via collaboration we can contribute to establishing new interests in the development of natural compounds for health.

Prof. Dr. Dominique Delmas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • silymarin: sources and biosynthesis
  • secondary metabolites and silymarin derivatives
  • silymarin bioavailability
  • silymarin and cardiovascular diseases
  • silymarin and metabolic syndrome
  • silymarin and cancer
  • silymarin and inflammation and immune diseases
  • silymarin and degenerative age-related diseases

Related Special Issue

Published Papers

This special issue is now open for submission.
Back to TopTop